Phase 2/3Suspended
Safety of F14 Following Total Knee Replacement
An Open Label Safety Study of a Single Administration of F14 in Patients Undergoing Unilateral Total Knee Replacement
- Sponsor
- Arthritis Innovation Corporation (Industry)
- Enrolment
- 100 planned
- Conditions
- Analgesia
- Interventions
- F14 (sustained release celecoxib)
- Ages
- adults, older adults
- Registry
- NCT04860635
Full record on ClinicalTrials.gov
From the registry
Open-label single-arm study in which all subjects receive F14 as part of a scheduled TKR and multimodal analgesia
Primary outcomes
- Incidence and severity of treatment-emergent adverse events (TEAEs)
History
Primary completion expected
Expected to start
Last registry update
Registered